ASCO 2026 Highlights – Part 2: Emerging Immunotherapy Strategies in Lung Cancer

ASCO 2026 Highlights – Part 2: Emerging Immunotherapy Strategies in Lung Cancer

In Part 2 of the ASCO 2026 Highlights series, hosts Dr. Narjust Florez and Dr. Stephen Liu are joined by Dr. Julie Brahmer and Dr. Solange Peters to discuss some of the most notable immunotherapy advances presented at the 2026 ASCO Annual Meeting. The conversation explores emerging data for PD-1/VEGF and PD-L1/VEGF bispecific antibodies, the growing role of antibody-drug conjugates in combination with immunotherapy, and promising new strategies targeting KRAS-mutant lung cancers, highlighting how these approaches may reshape the future treatment landscape. Guests: Julie R. Brahmer, MD, MSc, FASCO, FAIO The Marilyn Meyerhoff Professor of Thoracic Oncology Co-Leader, Cancer Immunology Research Program Co-Director, Upper Aerodigestive Cancers Program Director, Johns Hopkins Kimmel Cancer Center, Bayview Campus Professor Solange Peters, MD, PhD Chair of Medical Oncology Director of Oncology Department - CHUV Lausanne University Hospital

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(397)

LCC Advances in ALK+ Cancer in Cantonese

LCC Advances in ALK+ Cancer in Cantonese

As part of IASLC’s ongoing series of Lung Cancer Considered podcasts in world languages, Dr. Molly Li moderates a discussion in Cantonese with Dr. Tony Mok, Dr. Chao Zhang, and Dr. Wen-Zhao Zhong. The...

14 Aug 46min

Treating Advanced Thymic Cancers

Treating Advanced Thymic Cancers

Thymic epithelial tumors are rare but complex thoracic cancers that require specialized diagnosis and multidisciplinary management. In this episode of Lung Cancer Considered, Dr. Stephen Liu is joined...

4 Aug 59min

FDA Approval: Zidesamtinib and ROS1 NSCLC

FDA Approval: Zidesamtinib and ROS1 NSCLC

Patients with ROS1-positive NSCLC have a new treatment option following the FDA approval of zidesamtinib for those previously treated with a ROS1 tyrosine kinase inhibitor. In this episode, Dr. Stephe...

28 Jul 24min

Rewriting the Playbook: Cellular Therapy and Vaccines for ALK-Positive Lung Cancer

Rewriting the Playbook: Cellular Therapy and Vaccines for ALK-Positive Lung Cancer

How could cellular therapies and cancer vaccines transform the future of treatment for ALK-positive lung cancer? Host Dr. Narjust Florez sits down with Dr. Vincent Lam and Dr. Carmen Mecca to explore ...

21 Jul 47min

IASLC - Your First Faculty Job

IASLC - Your First Faculty Job

Starting your first faculty position can be both exciting and overwhelming. In this episode of Lung Cancer Considered, host Dr. Narjust Florez is joined by Dr. Arthi Sridhar to discuss the transition ...

7 Jul 41min

Game Changers & Hard Truths: Dr. Balazs Halmos Unfiltered

Game Changers & Hard Truths: Dr. Balazs Halmos Unfiltered

In this episode of Lung Cancer Considered, Dr. Balazs Halmos reflects on a career at the forefront of thoracic oncology, sharing the pivotal moments, lessons learned, and hard truths that have shaped ...

23 Jun 45min

Welcome to Seoul: 2026 World Conference on Lung Cancer (WCLC) Preview

Welcome to Seoul: 2026 World Conference on Lung Cancer (WCLC) Preview

This episode of Lung Cancer Considered provide a preview of the upcoming IASLC 2026 World Conference on Lung Cancer in Seoul, South Korea this September. Key topics covered include WCLC26 highlights -...

12 Jun 39min

Populært innen Vitenskap

fastlegen
tingenes-tilstand
romkapsel
jss
liberal-halvtime
rekommandert
villmarksliv
abels-tarn
dekodet-2
vett-og-vitenskap-med-gaute-einevoll
sinnsyn
fjellsportpodden
rss-overskuddsliv
rss-rekommandert
tomprat-med-gunnar-tjomlid
rss-inn-til-kjernen-med-sunniva-rose
hva-er-greia-med
rss-nysgjerrige-norge
diagnose
kvinnehelsepodden